Bioengineering and Stem Cell Technology in the Treatment of Congenital Heart Disease
1
Victor Chang Cardiac Research Institute, Lowy Packer Building, 405 Liverpool St., Darlinghurst NSW 2010, Australia
2
St. Vincent's Clinical School and School of Biotechnology and Biomolecular Sciences, University of New South Wales, Kensington NSW 2052, Australia
3
Control of Pluripotency Laboratory, Department of Physiological Sciences I, Faculty of Medicine, University of Barcelona, Hospital Clinic, Casanova 143, 08036 Barcelona, Spain
4
Senior Research Fellow, Sydney Medical School, University of Sydney, Sydney NSW 2006, Australia
5
School of Anatomy Physiology & Human Biology and The Harry Perkins Institute for Medical Research (CCTRM), Senior Research Fellow at the University of Western Australia, Crawley WA 6009, Australia
6
International Research Fellow, Victor Chang Cardiac Research Institute, Darlinghurst NSW 2010, Australia
7
Heart Centre for Children, The Children's Hospital at Westmead, Westmead NSW 2145, Australia
8
Sydney Medical School, University of Sydney, Sydney NSW 2006, Australia
9
Ear Science Institute Australia, Centre for Cell Therapy and Regenerative Medicine and School of Surgery, University of Western Australia, Nedlands WA 6009, Australia
*
Author to whom correspondence should be addressed.
Academic Editor: Jane Grant-Kels
J. Clin. Med. 2015, 4(4), 768-781; https://doi.org/10.3390/jcm4040768
Received: 22 December 2014 / Revised: 27 March 2015 / Accepted: 10 April 2015 / Published: 22 April 2015
(This article belongs to the Special Issue iPS Cells for Modelling and Treatment of Human Diseases)
Congenital heart disease places a significant burden on the individual, family and community despite significant advances in our understanding of aetiology and treatment. Early research in ischaemic heart disease has paved the way for stem cell technology and bioengineering, which promises to improve both structural and functional aspects of disease. Stem cell therapy has demonstrated significant improvements in cardiac function in adults with ischaemic heart disease. This finding, together with promising case studies in the paediatric setting, demonstrates the potential for this treatment in congenital heart disease. Furthermore, induced pluripotent stems cell technology, provides a unique opportunity to address aetiological, as well as therapeutic, aspects of disease.
View Full-Text
Keywords:
congenital heart disease; hypoplastic left heart; inducible pluripotential stem cells; bioengineered myocardium
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Bosman, A.; Edel, M.J.; Blue, G.; Dilley, R.J.; Harvey, R.P.; Winlaw, D.S. Bioengineering and Stem Cell Technology in the Treatment of Congenital Heart Disease. J. Clin. Med. 2015, 4, 768-781. https://doi.org/10.3390/jcm4040768
AMA Style
Bosman A, Edel MJ, Blue G, Dilley RJ, Harvey RP, Winlaw DS. Bioengineering and Stem Cell Technology in the Treatment of Congenital Heart Disease. Journal of Clinical Medicine. 2015; 4(4):768-781. https://doi.org/10.3390/jcm4040768
Chicago/Turabian StyleBosman, Alexis; Edel, Michael J.; Blue, Gillian; Dilley, Rodney J.; Harvey, Richard P.; Winlaw, David S. 2015. "Bioengineering and Stem Cell Technology in the Treatment of Congenital Heart Disease" J. Clin. Med. 4, no. 4: 768-781. https://doi.org/10.3390/jcm4040768
Find Other Styles
Search more from Scilit
